Gelation switch of polyamorphic indomethacin depending on the thermal procedure

Amorphous indomethacin (IMC) prepared under different thermal procedures via melt quenching method showed significantly different dissolution behaviors. This study aims to investigate the influence of thermal procedures on the formation of IMC polyamorphism and to explore the mechanism for their different dissolution behaviors. Amorphous IMC samples were prepared by melting crystalline IMC under a series of temperatures (160-195 °C), respectively, followed by quenching in liquid nitrogen. Samples obtained under 170 °C exhibited bi-halo shapes at ∼15° and ∼26° (2θ), while the ones above 175 °C showed a single halo at ∼21° (2θ), suggesting amorphous IMC prepared under different thermal procedures probably have different local molecular arrangements. In comparison to crystalline IMC, amorphous IMC obtained under 170 °C showed significantly higher dissolution profiles with good dispersibility in aqueous medium, however, all amorphous IMC samples prepared above 175 °C demonstrated much lower dissolution with significant gelation, which seemed like a gelation switch existed for polyamorphic IMC when the preparation temperature was between 170 and 175 °C. Based on physicochemical characterizations, amorphous IMC prepared under 170 °C had higher surface free energy, more surficial hydrophilic groups and better wettability than the ones made above 175 °C. Molecular dynamics simulations revealed that the amorphous samples prepared below 170 °C had similar binding energy values in the range of 310.045-325.479 kcal/mol, while those prepared above 175 °C were significantly lower within 212.193-235.073 kcal/mol. Such binding energy difference might be responsible for their different local molecular arrangements after different thermal procedures. The current study deeply reminds us that the thermal procedure of preparation methods may significantly affect the physicochemical properties of amorphous materials, which should be paid special attention to the polymorphic selection during pharmaceutical development.